A Phase I Study of Cabozantinib Plus Nivolumab (CaboNivo) Alone or in Combination With Ipilimumab (CaboNivoIpi) in Patients With Advanced/Metastatic Urothelial Carcinoma and Other Genitourinary Tumors

Trial Profile

A Phase I Study of Cabozantinib Plus Nivolumab (CaboNivo) Alone or in Combination With Ipilimumab (CaboNivoIpi) in Patients With Advanced/Metastatic Urothelial Carcinoma and Other Genitourinary Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 16 Aug 2017

At a glance

  • Drugs Cabozantinib (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary)
  • Indications Adenocarcinoma; Bladder cancer; Bone cancer; Germ cell and embryonal neoplasms; Penile cancer; Prostate cancer; Renal cell carcinoma; Squamous cell cancer; Urogenital cancer
  • Focus Adverse reactions
  • Sponsors Bristol-Myers Squibb; Exelixis
  • Most Recent Events

    • 02 Aug 2017 According to an Exelixis media release, data will be presented at the European Society for Medical Oncology (ESMO) 2017 Congress.
    • 06 Jun 2017 Results (n=30) assessing the safety and efficacy of cabozantinib plus nivolumab (CaboNivo) and cabonivo plus ipilimumab in patients with refractory metastatic urothelial carcinoma and other genitourinary tumors, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 06 Jun 2017 Results (n=27) assessing the feasibility of obtaining combined FDG and NaF PET/CT, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top